{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Woods EJ"],"funding":["National Institute of Allergy and Infectious Diseases"],"pagination":["300"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7405448"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["18(1)"],"pubmed_abstract":["<h4>Background</h4>Deceased organ donors represent an untapped source of therapeutic bone marrow (BM) that can be recovered in 3-5 times the volume of that obtained from living donors, tested for quality, cryopreserved, and banked indefinitely for future on-demand use. A challenge for a future BM banking system will be to manage the prolonged ischemia times that are inevitable when bones procured at geographically-dispersed locations are shipped to distant facilities for processing. Our objectives were to: (a) quantify, under realistic field conditions, the relationship between ischemia time and the quality of hematopoietic stem and progenitor cells (HSPCs) derived from deceased-donor BM; (b) identify ischemia-time boundaries beyond which HSPC quality is adversely affected; (c) investigate"],"journal":["Journal of translational medicine"],"pubmed_title":["Ischemia considerations for the development of an organ and tissue donor derived bone marrow bank."],"pmcid":["PMC7405448"],"funding_grant_id":["1R43AI129444-01A1"],"pubmed_authors":["Sherry AM","Woods EJ","Brandacher G","Woods JR","Hardin JW","LaFontaine M","Johnstone BH"],"additional_accession":[]},"is_claimable":false,"name":"Ischemia considerations for the development of an organ and tissue donor derived bone marrow bank.","description":"<h4>Background</h4>Deceased organ donors represent an untapped source of therapeutic bone marrow (BM) that can be recovered in 3-5 times the volume of that obtained from living donors, tested for quality, cryopreserved, and banked indefinitely for future on-demand use. A challenge for a future BM banking system will be to manage the prolonged ischemia times that are inevitable when bones procured at geographically-dispersed locations are shipped to distant facilities for processing. Our objectives were to: (a) quantify, under realistic field conditions, the relationship between ischemia time and the quality of hematopoietic stem and progenitor cells (HSPCs) derived from deceased-donor BM; (b) identify ischemia-time boundaries beyond which HSPC quality is adversely affected; (c) investigate","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Aug","modification":"2026-05-03T20:38:53.662Z","creation":"2020-08-15T07:03:25Z"},"accession":"S-EPMC7405448","cross_references":{"pubmed":["32758261"],"doi":["10.1186/s12967-020-02470-1"]}}